# Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT04714827** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanxi Province Cancer Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** KQ-2003 CAR-T cells

## Key facts

- **NCT ID:** NCT04714827
- **Lead sponsor:** Shanxi Province Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-22
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714827, "Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04714827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*